Key Takeaways
- Resilient quarter, guidance intact: EBITDA was close to the ₹1,100 cr FY23 target despite a maintenance shutdown, inflationary headwinds, and discretionary demand suppression. The FY24-25 EBITDA CAGR guidance of 25% was reaffirmed.
- Volume growth is the headline, but mix will dilute it: Management expects ~25% volume growth in FY24, but EBITDA growth is guided lower at ~15% because a portion of volumes will flow to lower-margin nonregular markets.
- A capex super-cycle is underway: The company guided for ₹3,000 cr in combined capex for FY24 and FY25, targeting new chemistries like chloro-toluene and downstream derivatives, with major volume contribution expected from FY26 onwards.
- Inventory destocking is a near-term drag: Discretionary end-markets are grappling with excess inventory at the customer level, pressuring Q1 FY24. Management expects a progressive, quarter-on-quarter improvement.
- What to watch next quarter: The pace of recovery from inventory destocking, the actual margin impact from nonregular market sales, and progress on the commercialization of the NCB expansion.
Demand Environment & Volume Outlook
- Discretionary demand suppressed: Products targeted at discretionary industries remained slow in Q4, consistent with prior warnings. The weakness is linked to inventory destocking driven by high financing costs, not a broad-based demand collapse.
- Agro and polymer markets sustaining: Demand in the agrochemical and polymer segments held up, though the agro portfolio is skewed toward generic products, which are facing product-specific inventory corrections.
- Inventory overhang concentrated downstream: Excess inventory sits at the ultimate customer and back-end supply chain. Customers are postponing purchases to reduce carrying costs, creating a Q1 headwind that management believes will ease progressively each quarter.
- Volume growth levers for FY24: Growth will be driven by market share gains, import substitution, and customer diversification, not just end-market recovery.
- Nonregular market as a pressure valve: To push volumes while regular demand is soft, the company is selling into nonregular markets (e.g., China), which carry gross margins that are 10-15% lower. This mix shift is the primary reason EBITDA growth will lag volume growth in FY24.
Rajendra Gogri: "Currently, at least Q1, definitely, there is pressure because of the inventories. And as we mentioned, it will be progressively that I think the situation will improve, i.e., quarter-on-quarter."
Financial Performance & Margin Walk
- Q4 EBITDA impacted by shutdowns: A maintenance shutdown at the Acid Unit and an opportunistic revamp at the Kutch Unit added ~₹10 cr in costs and reduced operating days, marginally pressuring the quarter.
- Revenue growth driven by capacity and mix: Q4 revenue grew 11% YoY, supported by higher volumes from expanded capacities for key products and a greater contribution from value-added products.
- Raw material and energy costs: Some normalization in energy costs was observed, but key raw material prices rose sequentially. Robust pass-through pricing mechanisms protected absolute profitability.
- PAT included a one-time tax benefit: Depreciation rose due to newly commercialized capacities, but PAT also benefited from a write-back of prior-period tax provisions after appeals were awarded in the company's favor.
- Opex run rate stabilizing: The Q4 opex run rate, adjusted for the maintenance shutdown, is expected to be the baseline going forward, with management not anticipating much increase in opex on an annualized basis through FY25.
- Working capital structurally lower: The demerger of the Pharma business, which historically carried higher working capital, and a product mix shift toward items with lower receivable credits have reduced working capital intensity.
Capex & Capacity Expansion
- FY24-25 capex guidance set at ₹3,000 cr: The company plans to deploy ~₹1,500 cr annually across FY24 and FY25, funded partially by internal accruals and partially by debt.
- Chloro-toluene and downstreams are the centerpiece: A significant portion of capex targets chloro-toluene and its downstream derivatives, a complex chemistry being introduced in India for the first time, aimed at import substitution and export opportunities.
- NCB expansion commercializing imminently: The nitro chlorobenzene plant expansion will be commercialized in Q1 FY24, with volumes starting from Q2. This will free up existing nitration capacity at other locations for new products.
- Long-term contract ramp-up underway: Contract 1 utilization is expected to move from 20-25% currently to 30-50% in FY24 and 70% by FY25. Contract 3 is expected to reach 60-70% utilization in FY25.
- Zone 4 is the FY26 growth story: The new chloro-toluene and multipurpose plants at Zone 4 will begin commissioning in FY25, with major volume contribution only from FY26 onwards.
- Acid division and ethylation capacity also expanding: Acid division capacity will expand by ~22% by end-FY24 or early FY25, while the ethylation plant will triple capacity with commissioning in FY25.
Rajendra Gogri: "I am excited with the upcoming opportunities in the chemical value-chain and truly believe that this is a 'Golden Decade' for us."
Competitive Dynamics & End-Market Risks
- No increase in Chinese competition: Management stated it is not seeing any increase in competitive intensity from China currently, and market share has been maintained despite the general slowdown.
- European energy dynamics are a structural tailwind: While the recent decrease in European energy prices benefits existing facilities there, management believes that on a long-term basis, growth in energy-intensive products in Europe will be curtailed, creating opportunity for Indian producers.
- Nonregular market margin dilution is temporary: The 10-15% lower gross margins on nonregular market sales are expected to correct by FY25, providing an additional EBITDA uplift as those volumes shift back to regular channels.
- Discretionary recovery expected progressively: Products linked to discretionary end-markets are expected to start recovering during FY24, though the timeline is tied to the pace of inventory normalization.
Rajendra Gogri: "Because in general, there will be a fear of higher energy cost in Europe. As far as the existing manufacturing facility in Europe is concerned, I think, definitely because of the decrease in energy prices in Europe, it will benefit them. But on a long-term basis, the energy intense products' growth in Europe will be curtailed."
Long-Term Contracts & Specialty Chemical Blocks
- Two specialty chemical blocks commercialized in H2FY23: The blocks at Jhagadia, built with ~₹300 cr in capex, operate in an EBITDA range of 25-30%. Exact sales numbers were not disclosed.
- Third long-term contract facility also commercialized: The facility for the third long-term contract came online in H2FY23, adding to the contract portfolio, though cumulative FY23 revenue from all three contracts was not provided on the call.
- Nitric acid supply de-risked for 20 years: A long-term off-take agreement for Nitric Acid, a key raw material, secures supply for two decades, significantly de-risking the business model for the contract portfolio.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | ~25% volume growth expected | FY24 |
| EBITDA growth | ~15% EBITDA growth expected (lower than volume growth due to nonregular market mix) | FY24 |
| EBITDA CAGR | 25% EBITDA CAGR guidance maintained | FY24 & FY25 |
| Capex | Combined capex of ₹3,000 cr (~₹1,500 cr annually) | FY24 & FY25 |
| NCB expansion commercialization | Plant commercialized, volumes to start | Q1 FY24 (commercialization), Q2 FY24 (volumes) |
| Contract 1 utilization ramp | Move from 20-25% to 30-50% utilization | FY24 |
| Contract 1 utilization ramp | Reach 70% utilization | FY25 |
| Contract 3 utilization ramp | Reach 60-70% utilization | FY25 |
| Nonregular market margin recovery | Volume going to nonregular market to correct, providing additional EBITDA uplift | FY25 |
| Zone 4 chloro-toluene and multipurpose plants | Commissioning to start; major volume growth from FY26 onwards | FY25 (commissioning start) |
| Acid division capacity expansion | Capacity expansion by ~22% | End-FY24 / early FY25 |
| Ethylation plant capacity | Triple capacity, commissioning | FY25 |
| Operating EBITDA guidance | ₹1,700 cr operating guidance maintained | FY25 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹1,826 cr, +11% YoY; exports contributed over 48% |
| EBITDA | ₹252 cr, vs ₹262 cr in Q4 FY22 |
| EBITDA margin | 13.8%, vs 15.1% in Q4 FY22 (per an analyst's math) |
| Profit after tax | ₹149 cr, vs ₹145 cr in Q4 FY22 |
| FY23 revenue | ₹7,283 cr, +17% YoY |
| FY23 EBITDA | ₹1,089 cr, +19% over normalised EBITDA of ₹919 cr in FY22 |
| FY23 PAT | ₹545 cr |
| FY23 capex | over ₹1,300 cr |
| FY24–25 annual capex target | ₹1,500 cr per year, combined ₹3,000 cr over two years |
| FY24 volume growth guidance | ~25%, with EBITDA growth lower at around 15% as part of volumes go to non-regular markets |
| FY24–25 EBITDA CAGR guidance | 25%, unchanged; FY25 EBITDA guidance of ₹1,700 cr maintained |
| Nitrochlorobenzene production | 18,842 MT |
| Hydrogenation production | 3,315 TPM |
| Nitro-Toluene production | 6,130 MT |
| PDA production | 348 TPM |
| Exports share (FY23) | ~48% of total revenues |
| Maintenance shutdown impact | ~₹10 cr in higher costs, with some volume impact from lower operating days |
| Long-term contract 1 utilization | ~20% currently, expected to reach 30–50% in FY24 |
| Long-term contract 3 utilization target (FY25) | 60–70% |
| Non-regular market margin differential | 10–15% lower gross margin vs regular markets |
| Non-regular market volume share | ~5–10% of total basket |
| Cash conversion cycle (FY23) | ~110 days |
| Tax rate guidance (FY24) | 15–17% |
| Total dividend per share (FY23) | ₹2.50, 50% of face value |
| Debt repayment obligation (FY24) | ~₹350 cr, evenly spread across quarters |
| Bank line utilization | ₹1,400–1,500 cr out of ₹1,800–2,000 cr CC lines |